Pluristem names new vice president of R&D
Fri. February 13, 2009; Posted: 07:55 AM
Feb 13, 2009 (Datamonitor via COMTEX) -- PSTI | Quote | Chart | News | PowerRating -- Pluristem Therapeutics, a biotherapeutics company engaged in the commercialization of allogeneic cell therapy products, has appointed Frida Grynspan as its new vice president of R&D, effective March 1, 2009.
Dr Grynspan will report directly to Zami Aberman, chairman, president and CEO of Pluristem.
Prior to joining Pluristem, Dr Grynspan served as vice president of R&D of a cell therapy company in Israel, where she was instrumental in bringing its first cell therapy product to a multinational, multi-center Phase III clinical trial and participated in the development of its pipeline.
Before that, Dr Grynspan served as a senior scientist at Intelligene, a developer of molecular biology diagnostic and therapeutic tools, and as an instructor and biochemist at Harvard Medical School.
Mr Aberman said: "Dr Grynspan has over 10 years of extensive professional experience in the field of human cell therapy and will be a valuable addition to Pluristem's management and R&D team. Her experience will greatly benefit Pluristem, as the company is progressing towards its Phase I clinical trial with PLX-PAD and broadening its products' pipeline."
datamonitor.com |
